Loading...
•
Sep 30, 2024
Surmodics Q4 2024 Earnings Report
Surmodics reported strong Q4 2024 financial results with revenue growth and advancements in medical device segment.
Key Takeaways
Surmodics reported a 19% year-over-year increase in total revenue for Q4 2024, driven by strong performance in the Medical Device segment. The company's GAAP net loss was $(3.4) million, while adjusted EBITDA reached $4.4 million.
Total revenue increased by 19% year-over-year to $33.2 million.
Medical Device revenue grew by 22% to $25.8 million, driven by vascular interventional products and performance coating reagents.
GAAP net loss was $(3.4) million, compared to net income of $6.7 million in the prior-year period.
Adjusted EBITDA was $4.4 million, compared to $1.7 million in the prior-year period.
Revenue by Segment
Forward Guidance
Surmodics is not introducing financial guidance for fiscal year 2025 due to the pending acquisition by GTCR.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...